Bioequivalence signifies that the rate and extent of absorption for the active ingredients-amoxicillin and clavulanic acid-are similar to the reference formulation when measured in the systemic circulation. It ensures that the active molecules reach the target tissues at levels recognized by regulatory authorities to achieve the intended pharmacological activity.
The presence of multiple WHO-GMP compliant manufacturers creates a diverse supply network for standard chemical compounds. This distribution model relies on the ability of international facilities such as Cipla to synthesize common active pharmaceutical ingredients at scale, which optimizes the logistical flow of therapeutics across borders.
Variations in color, coating, or tablet dimensions are common in international generic manufacturing and reflect the specific excipient (inert binding materials) formulations used by different WHO-GMP compliant facilities. These physical differences do not change the concentration or pharmaceutical activity of the amoxicillin and clavulanic acid.
Amoxicillin and clavulanic acid are moisture-sensitive. Stability is maintained by adhering to stated temperature ranges and keeping the product in the provided packaging until administration. Exposure to heat or humidity may impact the structural integrity of the compounds.
The Health Sciences Authority (HSA) provides specific guidelines regarding the import of health products for personal use. These rules typically require that the medication be for the personal use of the importer or their immediate family. Regulations are subject to change; therefore, users must verify current import criteria directly through the official HSA portal before initiating an order.
Amoxicillin and clavulanic acid are not typically targeted by standard workplace or clinical drug panels, which generally look for controlled or illicit substances. Detection panels vary by jurisdiction and the specific requirements of the testing institution.
The efficacy of the formulation is dictated by the chemical synthesis of the active ingredients, which is standardized by strict adherence to WHO-GMP protocols across international facilities. The synthesis process focuses on achieving the established pharmacopeial standards for purity and concentration, regardless of the individual manufacturing facility.
Formulated as a combination tablet, Advent DT contains amoxicillin and clavulanic acid in a 400/57mg dosage ratio. This therapeutic combination is produced by Cipla and is intended for use in the clinical management of specific bacterial infections where the presence of beta-lactamase (an enzyme that breaks down certain antibiotics) is suspected.
The inclusion of two distinct active pharmaceutical ingredients serves to address both the targeted bacterial strain and the resistance mechanism employed by the pathogen. Amoxicillin acts as the bactericidal agent, while clavulanic acid acts as a suicide inhibitor (a molecule that binds irreversibly to an enzyme to deactivate it) of beta-lactamase enzymes, thereby extending the spectrum of activity for the amoxicillin component.
Amoxicillin binds to penicillin-binding proteins (PBPs), which are enzymes located within the bacterial cell wall. This binding inhibits the final stages of peptidoglycan (the structural polymer of the bacterial cell wall) synthesis. By disrupting the structural integrity of the cell wall, the bacterium becomes susceptible to osmotic lysis (the breakdown of the cell due to internal pressure).
Clavulanic acid functions as a competitive and irreversible inhibitor of class A beta-lactamases. Many bacteria produce these enzymes to neutralize penicillins before they can reach their target. By binding to these enzymes, clavulanic acid prevents the degradation of amoxicillin, allowing the antibiotic to successfully reach and bind to the PBP targets within the pathogen. These processes act independently through distinct molecular pathways but are combined to enhance the targeted antibacterial intervention.
Documentation from the Health Sciences Authority (HSA) recognizes the efficacy of the combination of amoxicillin and clavulanic acid in the therapeutic setting. This formulation serves as a standard intervention for the management of respiratory tract infections, urinary tract infections, and infections of the skin and soft tissues caused by susceptible pathogens. The combination is indicated only for infections where the production of beta-lactamase by the infecting bacteria has been confirmed or is clinically suspected.
Individuals with a documented history of severe allergic reactions to penicillin or other beta-lactam antibiotics are contraindicated for this medication. A physician must be consulted to determine if an alternative therapeutic class is suitable.
A documented history of hepatic impairment (reduced liver function) or cholestatic jaundice (a condition where bile flow is blocked) associated with the use of amoxicillin and clavulanic acid prohibits the administration of this formulation. Clinical consultation is required to assess existing liver health records.
The combination of amoxicillin and clavulanic acid is categorised as a pregnancy risk where the potential benefits must be evaluated against the potential for adverse effects on the fetus. These compounds are excreted into breast milk. Any decision regarding use during pregnancy or lactation must be directed by a primary care physician or obstetrician.
The clinical administration of this formulation requires that the tablet be swallowed with an adequate amount of water to assist with the transit into the digestive tract. Food intake at the start of administration may be observed to minimize potential gastrointestinal discomfort, though this does not alter the pharmacokinetic properties of the compounds. Decisions concerning the duration of use, escalation, or frequency of administration are reserved exclusively for the supervising physician based on the specific clinical requirements of the patient.
Store this medication at room temperature in a dry environment to maintain molecular stability. Exposure of the formulation to high humidity or light conditions may accelerate the degradation of the active ingredients. Expiration dates are indicated on the manufacturer packaging. Dispose of any expired or unused units in accordance with the local pharmaceutical waste guidelines managed by Singapore authorities.
Advent DT is produced by Cipla in WHO-GMP compliant facilities and is accessible through international logistics networks. This platform functions as an international logistics offer intermediary, facilitating the identification and transit of these formulations from external synthesis sites. Confirmed orders are redirected to an external third-party payment processor.
This content is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. This platform acts solely as an international logistics offer intermediary and is not a pharmacy, clinic, or prescriber. Any decision to use a medication must be made in consultation with a physician licensed to practice in Singapore. Users are responsible for ensuring that all imports comply with the Health Sciences Authority (HSA) regulations regarding personal medication use. Review the provided original package insert for detailed clinical guidance.
